WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315140

CAS#: 274901-16-5

Description: Vildagliptin (also known as LAF237 and Zomelis) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus. Novartis has since withdrawn its intent to submit vildagliptin to the FDA, as of July 2008. T it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.

Chemical Structure

CAS# 274901-16-5

Theoretical Analysis

MedKoo Cat#: 315140
Name: Vildagliptin
CAS#: 274901-16-5
Chemical Formula: C17H25N3O2
Exact Mass: 303.19468
Molecular Weight: 303.41
Elemental Analysis: C, 67.30; H, 8.31; N, 13.85; O, 10.55

Size Price Shipping out time Quantity
1g USD 150 Same day
2g USD 250 Same day
5g USD 450 Same day
10g USD 750 Same day
20g USD 1250 Same day
50g USD 1950 Same day
100g USD 2950 Same day
Inquire bulk and customized quantity

Pricing updated 2021-02-26. Prices are subject to change without notice.

Vildagliptin, purity > 98%, is in stock. The same day shipping after order is received.

Synonym: LAF237; LAF-237; LAF 237; DSP 7238; DSP-7238; DSP7238; Vildagliptin; Zomelis

IUPAC/Chemical Name: (S)-1-(2-(((1s,3R,5R,7S)-3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile


InChi Code: InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12-,13+,14-,16-,17-/m0/s1

SMILES Code: N#C[C@H]1N(C(CN[C@@]23C[C@@]4(O)C[C@](C3)([H])C[C@@](C4)([H])C2)=O)CCC1

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Preparing Stock Solutions

The following data is based on the product molecular weight 303.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Aziz KM. Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients. Diabetes Metab Syndr Obes. 2015 Apr 16;8:207-11. doi: 10.2147/DMSO.S54683. eCollection 2015. Review. PubMed PMID: 25931826; PubMed Central PMCID: PMC4404947.

2: Forst T, Bramlage P. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Expert Opin Pharmacother. 2014 Jun;15(9):1299-313. doi: 10.1517/14656566.2014.920009. Review. PubMed PMID: 24837407.

3: Stein SA, Lamos EM, Davis SN. Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):599-608. doi: 10.1517/17425255.2014.889683. Epub 2014 Feb 19. Review. PubMed PMID: 24547938.

4: Kožnarová R. [Use of vildagliptin from an internal disease specialists point of view]. Vnitr Lek. 2013 Apr;59(4):322-4. Review. Czech. PubMed PMID: 23711060.

5: Khan S, Khan S, Imran M, Pillai KK, Akhtar M, Najmi AK. Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis. Expert Opin Ther Targets. 2013 Jun;17(6):627-39. doi: 10.1517/14728222.2013.764991. Epub 2013 Jan 28. Review. PubMed PMID: 23356568.

6: Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012;8:339-48. doi: 10.2147/VHRM.S31758. Epub 2012 May 18. Review. PubMed PMID: 22661900; PubMed Central PMCID: PMC3363148.

7: Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. Expert Opin Pharmacother. 2012 Jun;13(9):1377-84. doi: 10.1517/14656566.2012.667078. Epub 2012 Mar 7. Review. PubMed PMID: 22397507.

8: He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. doi: 10.2165/11598080-000000000-00000. Review. PubMed PMID: 22339447.

9: Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J Clin Pharm Ther. 2012 Aug;37(4):386-98. doi: 10.1111/j.1365-2710.2011.01323.x. Epub 2011 Dec 22. Review. PubMed PMID: 22191695.

10: Kalra S. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. J Assoc Physicians India. 2011 Apr;59:237-45. Review. PubMed PMID: 21755761.